×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TARA – protara therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TARA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
04:05 pm
tara
Protara Announces Closing of $100 Million Public Offering
Low
Report
Protara Announces Closing of $100 Million Public Offering
12/9
11:35 pm
tara
Protara Announces Pricing of $100 Million Public Offering
Neutral
Report
Protara Announces Pricing of $100 Million Public Offering
12/9
04:19 pm
tara
Protara Announces Proposed Public Offering [Yahoo! Finance]
Low
Report
Protara Announces Proposed Public Offering [Yahoo! Finance]
12/9
04:01 pm
tara
Protara Announces Proposed Public Offering
Medium
Report
Protara Announces Proposed Public Offering
12/7
09:08 am
tara
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most [Yahoo! Finance]
High
Report
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most [Yahoo! Finance]
12/6
12:10 pm
tara
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $20.00 price target on the stock.
Low
Report
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $20.00 price target on the stock.
12/6
10:57 am
tara
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy [Yahoo! Finance]
Medium
Report
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy [Yahoo! Finance]
12/6
08:13 am
tara
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
High
Report
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
08:00 am
TARA
protara therapeutics, inc.
IN-LINE
Report
-4.1%
protara therapeutics, inc.
8/6/2024
08:00 am
TARA
protara therapeutics, inc.
BEAT
Report
0.0%
protara therapeutics, inc.
5/2/2024
08:00 am
TARA
protara therapeutics, inc.
BEAT
Report
-0.3%
protara therapeutics, inc.
3/13/2024
08:00 am
TARA
protara therapeutics, inc.
BEAT
Report
2.2%
protara therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/17
04:02 pm
tara
Form SC 13G Protara Therapeutics, Filed by: Velan Capital Investment Management LP
Medium
Report
Form SC 13G Protara Therapeutics, Filed by: Velan Capital Investment Management LP
12/11
04:19 pm
tara
Form 8-K Protara Therapeutics, For: Dec 09
Low
Report
Form 8-K Protara Therapeutics, For: Dec 09
12/11
07:31 am
tara
Form 424B5 Protara Therapeutics,
Low
Report
Form 424B5 Protara Therapeutics,
12/9
04:18 pm
tara
Form 424B5 Protara Therapeutics,
Low
Report
Form 424B5 Protara Therapeutics,
12/5
08:46 am
tara
Form 8-K Protara Therapeutics, For: Dec 05
High
Report
Form 8-K Protara Therapeutics, For: Dec 05
11/18
06:02 am
tara
Form SC 13G Protara Therapeutics, Filed by: Opaleye Management Inc.
High
Report
Form SC 13G Protara Therapeutics, Filed by: Opaleye Management Inc.
11/14
01:01 pm
tara
Form SC 13G Protara Therapeutics, Filed by: Woodline Partners LP
Low
Report
Form SC 13G Protara Therapeutics, Filed by: Woodline Partners LP
11/14
12:20 pm
tara
Form SC 13G/A Protara Therapeutics, Filed by: CVI Investments, Inc.
Low
Report
Form SC 13G/A Protara Therapeutics, Filed by: CVI Investments, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 8-K ArTara Therapeutics, For: Mar 18
14.2%
1/21 Form SC 13D ArTara Therapeutics, Filed by: Opaleye Management Inc. 12.8%
2/4 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.9%
3/30 Form 8-K ArTara Therapeutics, For: Mar 26 6.5%
4/21 Verona Pharma plc (NASDAQ: TARA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/11 Form 424B3 ArTara Therapeutics, 4.6%
4/2 ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 4.3%
1/15 Form S-8 ArTara Therapeutics, 3.7%
2/14 Form SC 13G/A ArTara Therapeutics, Filed by: INTERSOUTH PARTNERS VI LP 2.7%
4/23 Form DEF 14A ArTara Therapeutics, For: Jun 09 2.5%
1/21 Form SC 13D ArTara Therapeutics, Filed by: Opaleye Management Inc. 12.8%
2/4 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.9%
3/30 Form 8-K ArTara Therapeutics, For: Mar 26 6.5%
4/21 Verona Pharma plc (NASDAQ: TARA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/11 Form 424B3 ArTara Therapeutics, 4.6%
4/2 ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 4.3%
1/15 Form S-8 ArTara Therapeutics, 3.7%
2/14 Form SC 13G/A ArTara Therapeutics, Filed by: INTERSOUTH PARTNERS VI LP 2.7%
4/23 Form DEF 14A ArTara Therapeutics, For: Jun 09 2.5%
TOP News Decliners
2/21
Form SC 13G ArTara Therapeutics, Filed by: Ikarian Capital, LLC
-7.6%
4/9 Form SEC STAFF LETTER ArTara Therapeutics, -6.1%
3/20 Form 10-K ArTara Therapeutics, For: Dec 31 -4.6%
4/18 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. -4.5%
1/30 Form S-3 ArTara Therapeutics, -4.0%
1/13 Form 3 ArTara Therapeutics, For: Jan 09 Filed by: Opaleye, L.P. -3.6%
2/18 Form 4/A ArTara Therapeutics, For: Jan 09 Filed by: Shefferman Jesse -3.1%
1/27 Form SC 13D/A ArTara Therapeutics, Filed by: Opaleye Management Inc. -1.6%
1/16 Form SC 13G ArTara Therapeutics, Filed by: Wilson Donald R. Jr. -0.6%
4/9 Form SEC STAFF LETTER ArTara Therapeutics, -6.1%
3/20 Form 10-K ArTara Therapeutics, For: Dec 31 -4.6%
4/18 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. -4.5%
1/30 Form S-3 ArTara Therapeutics, -4.0%
1/13 Form 3 ArTara Therapeutics, For: Jan 09 Filed by: Opaleye, L.P. -3.6%
2/18 Form 4/A ArTara Therapeutics, For: Jan 09 Filed by: Shefferman Jesse -3.1%
1/27 Form SC 13D/A ArTara Therapeutics, Filed by: Opaleye Management Inc. -1.6%
1/16 Form SC 13G ArTara Therapeutics, Filed by: Wilson Donald R. Jr. -0.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: